Search research articles
Contact Us
Filters
Showing results (161-170 of 179) with videos related to
Page
of 18
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging
|
August 9, 2012
Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrest
Mario Vallon, Christof Seidl, Birgit Blechert, et al.
AIDS (London, England)
|
November 24, 2015
A fully human antibody to gp41 selectively eliminates HIV-infected cells that transmigrated across a model human blood brain barrier
Alicia McFarren, Lillie Lopez, Dionna W Williams, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 19, 2019
Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving <sup>225</sup>Ac-PSMA-617 Radioligand Therapy
Mike Sathekge, Frank Bruchertseifer, Mariza Vorster, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
September 13, 2024
Survival impact of [<sup>225</sup>Ac]Ac-DOTATOC alpha-therapy in a preclinical model of pancreatic neuroendocrine tumor liver micrometastases
Alexandre Lugat, Nicolas Chouin, Florian Chocteau, et al.
Cancers
|
April 25, 2020
Preclinical Targeted α- and β<sup>-</sup>-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies
Janik Puttemans, Yana Dekempeneer, Jos L Eersels, et al.
European Urology
|
December 9, 2020
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA
Benedikt Feuerecker, Robert Tauber, Karina Knorr, et al.
Oncotarget
|
January 11, 2015
α-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma
Katharina Teiluf, Christof Seidl, Birgit Blechert, et al.
Molecular Cancer Therapeutics
|
October 20, 2021
The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy
Janik Puttemans, Benoit Stijlemans, Marleen Keyaerts, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 23, 2010
Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia
Todd L Rosenblat, Michael R McDevitt, Deborah A Mulford, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 13, 2023
Targeted α-Therapy Using <sup>225</sup>Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment
Thomas Ertveldt, Ahmet Krasniqi, Hannelore Ceuppens, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 179) with videos related to
Sort By:
Page
of 18
European Journal of Nuclear Medicine and Molecular Imaging
|
August 9, 2012
Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrest
Mario Vallon, Christof Seidl, Birgit Blechert, et al.
AIDS (London, England)
|
November 24, 2015
A fully human antibody to gp41 selectively eliminates HIV-infected cells that transmigrated across a model human blood brain barrier
Alicia McFarren, Lillie Lopez, Dionna W Williams, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 19, 2019
Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving <sup>225</sup>Ac-PSMA-617 Radioligand Therapy
Mike Sathekge, Frank Bruchertseifer, Mariza Vorster, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
September 13, 2024
Survival impact of [<sup>225</sup>Ac]Ac-DOTATOC alpha-therapy in a preclinical model of pancreatic neuroendocrine tumor liver micrometastases
Alexandre Lugat, Nicolas Chouin, Florian Chocteau, et al.
Cancers
|
April 25, 2020
Preclinical Targeted α- and β<sup>-</sup>-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies
Janik Puttemans, Yana Dekempeneer, Jos L Eersels, et al.
European Urology
|
December 9, 2020
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA
Benedikt Feuerecker, Robert Tauber, Karina Knorr, et al.
Oncotarget
|
January 11, 2015
α-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma
Katharina Teiluf, Christof Seidl, Birgit Blechert, et al.
Molecular Cancer Therapeutics
|
October 20, 2021
The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy
Janik Puttemans, Benoit Stijlemans, Marleen Keyaerts, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 23, 2010
Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia
Todd L Rosenblat, Michael R McDevitt, Deborah A Mulford, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 13, 2023
Targeted α-Therapy Using <sup>225</sup>Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment
Thomas Ertveldt, Ahmet Krasniqi, Hannelore Ceuppens, et al.
Page
of 18